Pyrazole Xanthohumol Derivatives That Prevent Estrogenic Isomerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for metabolic syndrome, obesity, and cardiovascular disease are inadequate, with xanthohumol derivatives like xanthohumol potentially causing estrogenic side effects due to isomerization into isoxanthohumol, and current flavonoids providing only marginal to modest thermogenic effects.
Innovation Solution
Development of xanthohumol derivatives with cyclic moieties such as pyrazole or isoxazole to prevent isomerization, increasing energy expenditure and improving glucose tolerance, including compounds like 4-(5-(4-hydroxyphenyl)-1-methyl-1H-pyrazol-3-yl)-5-methoxy-2-(3-methylbut-2-en-1-yl)benzene-1,3-diol, which act as mitochondrial uncouplers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If xanthohumol is administered to treat metabolic syndrome and obesity, then weight gain is reduced and glucose metabolism is improved, but estrogenic side effects occur due isomerization into isoxanthohumol
Solution Approach 1:
The patent extracts and eliminates the problematic α,β-unsaturated ketone functional group from the xanthohumol structure by replacing it with a cyclic moiety (pyrazole, isoxazole, or similar 4-6 membered ring). This extraction of the harmful element prevents isomerization to isoxanthohumol while preserving the thermogenic and metabolic benefits of the original compound.
Solution Approach 2:
The patent changes the chemical structure parameters of xanthohumol by introducing cyclic moieties at positions 2-4 of the chalcone backbone. This structural modification alters the chemical stability and metabolic pathway of the compound, preventing isomerization while maintaining or enhancing therapeutic effects on weight management and glucose metabolism.
2Use of energy by moving object
If current flavonoids are used to induce thermogenesis, then energy expenditure is increased, but the effect is only marginal to modest
Solution Approach 1:
The patent changes the molecular structure parameters of flavonoids by incorporating cyclic moieties (pyrazole, isoxazole, or other 4-6 membered rings) into the chalcone backbone. This structural modification enhances the thermogenic potency of the compound, transforming marginal effects into significant energy expenditure increases suitable for clinical obesity treatment.
Solution Approach 2:
The patent creates composite molecular structures by combining the chalcone scaffold with cyclic heterocyclic moieties. This composite structure integrates the beneficial properties of both components: the metabolic activity of flavonoids and the enhanced stability and potency of cyclic structures, resulting in superior thermogenic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These derivatives effectively reduce weight gain, improve glucose tolerance, and increase energy expenditure, offering significant anti-obesity and metabolic benefits without estrogenic side effects.
Implementation Method 1
compounds like 4-(5-(4-hydroxyphenyl)-1-methyl-1H-pyrazol-3-yl)-5-methoxy-2-(3-methylbut-2-en-1-yl)benzene-1,3-diol, which act as mitochondrial uncouplers
Data Source
AI summary
Representative xanthohumol derivatives have been made and have been tested in vivo in mice. Such derivatives have a number of important medicinal benefits, including improving glucose tolerance and decreasing weight gain by increasing energy expenditure and locomotor activity in treated subjects. Disclosed derivatives also may function as mitochondrial uncouplers. Representative compounds include 4-(5-(4-hydroxyphenyl)-1-methyl-1H-pyrazol-3-yl)-5-methoxy-2-(3-methylbut-2-en-1-yl)benzene-1,3-diol and 4-(5-(4-hydroxyphenyl)isoxazole-3-yl)-5-methoxy-2-(3-methylbut-2-en-1-yl)benzene-1,3-diol.